STOCK TITAN

Glaukos Corporation - GKOS STOCK NEWS

Welcome to our dedicated news page for Glaukos Corporation (Ticker: GKOS), a resource for investors and traders seeking the latest updates and insights on Glaukos Corporation.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Glaukos Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Glaukos Corporation's position in the market.

Rhea-AI Summary
Glaukos Corporation (NYSE: GKOS) announced its financial results for Q3 2023. Net sales increased by 10% YoY to $78.0 million. Glaucoma net sales rose by 9% YoY to $58.3 million, and Corneal Health net sales increased by 12% YoY to $19.7 million. Gross margin was approximately 76%, and non-GAAP gross margin was approximately 83%. The company raised its 2023 net sales guidance to $307 million to $310 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.58%
Tags
-
Rhea-AI Summary
Glaukos Corporation will feature its technologies in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting. The company will exhibit onsite at booth #1630. Key presentations include studies on the efficacy and safety of Glaukos' intraocular implants for glaucoma treatment, as well as innovations in collagen cross-linking for corneal health. The AAO Annual Meeting is a significant event in the ophthalmic industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
none
-
Rhea-AI Summary
Glaukos Corporation to release Q3 2023 financial results and hold conference call and webcast
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.99%
Tags
Rhea-AI Summary
Glaukos Corporation to participate in Wells Fargo Healthcare Conference on September 6, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
-
Rhea-AI Summary
Glaukos Corporation (NYSE: GKOS) announced a collaboration and marketing agreement with Radius XR, Inc. to market the Radius XR™ wearable patient engagement and diagnostic system in the US. The system aims to enable more efficient detection of eye diseases and better management of sight-threatening conditions, providing medical professionals with accurate diagnostics and patient engagement tools. Glaukos will be the exclusive sales agent for the system, leveraging its expertise to drive greater patient access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
none
Rhea-AI Summary
Glaukos Corporation (NYSE: GKOS) to discuss second quarter 2023 financial results in conference call and webcast. Management will address novel therapies for glaucoma, corneal disorders, and retinal diseases. Investors can participate by dialing 888-210-2212 (U.S.) or 646-960-0390 (International) and entering Conference ID 7935742.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Glaukos Corporation

NYSE:GKOS

GKOS Rankings

GKOS Stock Data

4.86B
47.54M
3.86%
105.02%
7.06%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
San Clemente

About GKOS

glaukos corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. glaukos has pioneered micro-invasive glaucoma surgery, or migs, to revolutionize the traditional glaucoma treatment and management paradigm. the company launched the istent trabecular micro-bypass stent, its first migs device, in the united states in 2012. glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. glaukos believes the istent is the smallest medical device ever approved by the food and drug administration, or fda, measuring 1.0 mm long and 0.33 mm wide. in june 2015, the company completed an initial public offering and its shares are now traded on the new york stock exchange unde